Parexel, a leading global clinical development partner, has acquired Vitrana, a provider of an AI-enabled, end-to-end pharmacovigilance (PV) technology platform. The financial terms of the deal remain undisclosed.

The acquisition further expands Parexel's technology capabilities to better serve customers. It provides an integrated PV platform that leverages intelligent automation and AI to accelerate end-to-end Patient Safety & PV processes, deliver first-time quality and enhance compliance.

"With Vitrana, we can now offer customers a single partner for both PV technology and services – and that changes what we can deliver for them. Our customers will benefit from best-in-class, technology-enabled PV services that handle growing regulatory volume and complexity, enhance compliance, streamline workflows, and enable experts to focus on what matters most: product and patient safety," said Sanjay Vyas, President of Patient Safety Services & Clinical Logistics and Managing Director of India, Parexel.

The acquisition delivers tangible benefits throughout the clinical trial ecosystem and post-approval market. It also reduces the burden on investigative sites through improved electronic data capture (EDC)-to-safety integration and streamlined Serious Adverse Event (SAE) reconciliation.

"We are thrilled to join Parexel and further scale our proven technology and our experienced team as we strengthen pharmacovigilance solutions," said Mohit Gupta, President and CEO, Vitrana. "Together, we can offer improved efficiency, quality and compliance for our customers worldwide."